DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Rad Oncology Homepage

Elekta Unity MR-linac gains FDA 510(k) clearance Simultaneously delivers radiation dose and visualization of tumors

Dr. Hermann Requardt United Imaging Healthcare appoints senior scientific advisor

Patient denied proton therapy dies, family received $25 million in court Points to the need for greater treatment coverage for certain cancer patients

Microbeam radiation therapy could lead to single session treatments Healthy cells tolerate treatment while tumors lose structure

CMS to unveil mandatory payment model for radiation oncology Part of determining approach that saves more and offers greater quality

European report says radiotherapy 'undervalued' and needing 'greater investment' Equipment shortages, lack of investment, training variations

ViewRay to supply UK's GenesisCare with country's first MRIdian systems Providing soft-tissue imaging in real time and better tumor targeting

Accuray showcases software upgrades for CyberKnife and Radixact at ASTRO Allows for 40 percent faster treatment delivery

Precision cancer care with proton and radiation oncology Some of the latest systems and software entering the market

IBA Dosimetry debuts myQA Daily at ASTRO 2018 Has 125 ionization chamber measurement points

Courtesy: University Hospitals
Seidman Cancer Center

Functional SBRT prostate imaging treatment advances to world’s first clinical trials

by John W. Mitchell , Senior Correspondent
Doctors at the University Hospitals Case Medical Center Seidman Cancer Center in Cleveland have launched a trial to evaluate a new stereotactic body radiotherapy (SBRT) that may greatly reduce treatment time, costs and serious side effects.

SBRT targets just part of the prostate, rather than the entire gland. “If successful this study may lead to a routine option to treat only part of the prostate containing cancer, instead of treating the entire prostate initially,” Dr. Rodney Ellis, lead author and Associate Professor of Radiation Oncology and Urology at Seidman told HCB News.

Story Continues Below Advertisement

Questions to ask and things to consider about MRI coil repair processes

What to Expect from MRI Coil Repairs that Meet Clinical Expectations and Drive ROI. Click for A Guideline of Standards to Expect and Demand for Sustainable MRI Coil Repairs

Side effects from whole prostate treatments include incontinence, loss of sexual function and risk of damage to the bladder and rectum associated with current whole gland radiation therapy. The trial’s first patient underwent treatment in early April with no reported side effects.

“The advantage [of SBRT] for patients is the ability to treat the cancer with anticipated fewer side effects. The reduction from nine weeks (current protocol) to three days of SBRT is also a tremendous cost savings.”

In 1998, Ellis was the first clinician to use functional imaging to escalate dose in the prostate gland using brachytherapy and SPECT/CT images, according to Seidman Cancer Clinic. The methodology for the current SBRT trial method was conceived in 2004 from his prior research.

“The recent addition of functional imaging to see the behavior of tissue in addition to standard MR images has opened new confidence in being able to locate the region of the prostate that has cancer,” Ellis explained. He added that it has become standard to use MRI to make a diagnosis by directing biopsies, rather than taking blind biopsies throughout the prostate to look for cancer.

The initial trial will include 12 patients. Ellis said that if they can confirm the SBRT findings, the team would seek additional funding to include more patients. Initial results have already been accepted for presentation at an international scientific conference in June.

If successful the study may lead to a routine option to treat only part of the prostate instead of the entire gland. But the idea could be applicable to other cancer patients.

“While this study and the results of the first patient appear to validate the patented methodology being used in the trial, it may be applicable for other types of cancer and for non-radiation-based treatments as well,” said Ellis.

He added that the SBRT study has multiple objectives. It is evaluating the ability to confirm that MR findings truly represent cancer. The study will define the volume of the gland that needs to be treated beyond the measurable MR findings to be sure that microscopic parts of the disease are also treated. And finally the trial will be seeking to improve quality of life by reducing or eliminating side effects.

According to American Cancer Society estimates, in 2016 there will be 26,000 deaths from prostate cancer, with 181,000 new cases diagnosed. About one in seven men will develop the disease in their lifetime, primarily in older men. And the National Cancer Institute notes that 80 percent of prostate cancer is identified in the early stage, when lesions are still localized in the prostate.

Rad Oncology Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2018, Inc.